Patents
Promoting cardiac cell differentiation
Patent Number: 7,271,254This patent covers the composition of matter for the myofibrillogenesis-inducing RNA (MIR) molecule. MIR appears to be important for myofibrillogenesis (a stage in cardiogenesis) in a type of salamander called the Mexican axolotl. Since the claims cover composition of matter for a molecule found on a non-human species, it will be interesting to see how commercialization of this patent will be...
Inventors: Lemanski; Larry F. (Boynton Beach, FL), Zhang; Chi (Pompano Beach, FL)
Assignee: Florida Atlantic University (Boca Raton, FL)
Date of First Priority Issue: Thursday April 10th, 2003
Agents for preventing and treating thrombocytopenia
Patent Number: 7,268,110Parathyroid hormone is a polypeptide secreted by the parathyroid gland in order to regulate calcium concentrations in the blood. Low calcium levels stimulate secretion of parathyroid hormone which in turn activates osteoclasts to release calcium deposits from bone. The use of parathyroid hormone to modulate stem cells has been demonstrated clinically by Ballen et al who showed that
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Date of First Priority Issue: Thursday February 1st, 1996
Methods of promoting osteogenesis
Patent Number: 7,268,139This patent covers the composition of matter for a small molecule inhibitor of p38 MAP kinase, as well as the use of these compounds for stimulation/acceleration of bone healing. Presumably since p38 is involved in inflammatory signaling, the inhibition of this pathway allows for regenerative activities to prevail, thus allowing healing unimpeded by inflammation. Indeed one of the claims does...
Inventors: Protter; Andrew A. (Palo Alto, CA), Liu; David Y. (Palo Alto, CA), O'Connor; Patrick (Farnwood, NJ)
Assignee: Scios, Inc. (Fremont, CA)
Date of First Priority Issue: Thursday August 29th, 2002
Human foreskin fibroblasts for culturing ES cells
Patent Number: 7,267,981Human embryonic stem cells were classically grown on mouse feeder layers. Unfortunately these cells can not be clinically used since numerous adventitious viruses and infectious agents exist that theoretically can infect humans. The current patent teaches the use of human foreskin fibroblasts as feeder layers for growing embryonic stem cells. Foreskin fibroblasts are conventionally used for...
Inventors: Amit; Michal (Misgav, IL), Itskovitz-Eldor; Joseph (Haifa, IL)
Assignee: Technion Research & Development Foundation Ltd. (Haifa, IL)
Date of First Priority Issue: Monday October 7th, 2002
Treatment for wounds
Patent Number: 7,262,174The use of epithelial cells (such as fibroblasts) transfected with telomerase for acceleration of wound healing is covered by this patent. This invention is conceptually attractive, however the possible effects of telomerase transfection in terms of immortalization of cells showed be consided. Since wounds already express inflammatory mediators such as free radicals (which damage DNA), would not...
Inventors: Jiang; Xu-Rong (Mountain View, CA), Chiu; Choy-Pik (Cupertino, CA), Harley; Calvin B. (Palo Alto, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Wednesday May 9th, 2001
Synthetic oligonucleotides as inducers of erythroid differentiation
Patent Number: 7,262,175This patent covers synthetic oligonucleotides (composition of matter) derived from promoter of gamma globulin, which stimulate erthrocytic differentiation. The patent is useful for treatment of patients post chemotherapy increase hemoglobin counts, and also for development of in vitro erythrocyte culture systems. The mechanism by which these oligonucleotides work appears unclear.
Inventors: Bianchi; Nicoletta (Mezzogoro, IT), Feriotto; Giordana (Occhiobello, IT), Gambari; Roberto (Bologna, IT), Mischiati; Carlo (Occhiobello, IT)
Assignee: Universita' Degli Studi Di Ferrara (Ferrara, IT)
Date of First Priority Issue: Saturday May 13th, 2000
Numb protein expression inhibitors by Musashi
Patent Number: 7,264,793Musashi is a protein found on stem cells of the neural lineage. This patent covers the administration of Musashi to increase proliferation of neural stem cells. The patent also covers the use of Musashi to inhibit the repressor of Notch signalling Numb and thereby sensitize neural stem cells to proliferative/expansionive signals.
Inventors: Imai; Takao (Tokyo, JP), Tokunaga; Akinori (Tokyo, JP), Yoshida; Tetsu (Tokyo, JP), Mikoshiba; Katsuhiko (Tokyo, JP), Nakafuku; Masato (Tokyo, JP), Okano; Hideyuki (Tokyo, JP)
Assignee: Japan Science and Technology Corporation (Kawaguchi-shi, JP)
Date of First Priority Issue: Thursday May 31st, 2001
Method of inducing and maintaining neuronal cells
Patent Number: 7,264,968This patent covers methods of generating cells with a neuronal phenotype from cells that possess the activin receptor. Specifically, the invention provides the finding that ectodermal tissue can be induced to differentiate into neuronal tissues by inhibiting signaling of the activin receptor. This patent has very broad reaching consequences since conceptually it covers activin receptor...
Inventors: Melton; Douglas A. (Lexington, MA), Hemmati-Brivanlou; Ali (New York, NY)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Tuesday October 14th, 2003
Telomerizing nuclear donor cells and improving the efficiency on nuclear transfer
Patent Number: 7,265,262This patent covers methods of generating transgenic animals through the use of donor cells that express the telomerase reverse transcriptase. The expression of telomerase in the donor cell apparently increases the efficacy of cloning. There are 4 independent claims in the patent, all covering "a method for generating transgenic non-primate mammals by nuclear transfer", and all containing...
Inventors: Clark; A. John (Midlothian, GB), Cui; Wei (Midlothian, GB), Denning; Chris (Loughborough, GB), Zhao; Debbiao (Midlothian, GB)
Assignee: Roslin Institute (Edinburgh) (Roslin, Midlothian, GB)
Date of First Priority Issue: Wednesday March 21st, 2001
Pluripotent adult stem cells
Patent Number: 7,259,011This patent covers a stem cell that is positive for expression of CD13, CD34, CD56 and CD117, negative for CD10. Dependent claims further cover the phenotype of CD2, CD5, CD14, CD19, CD33, CD45, and DRII negative, CD13,CD34, CD56, CD90, CD117 positive, and CD2, CD3, CD10, CD14, CD16, CD31, CD33, CD45 and CD64 negative. The stem cell can be derived from the muscle or bone marrow. The...
Inventors: Lucas; Paul (Poughkeepsie, NY), Schultz; Sherri (Katonah, NY), Pine; Sharon P. (Montgomery Village, MD)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday May 20th, 2004